NYHA FC and Finerenone Response: Clinical Trial Insights

Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves patient outcomes in HFmrEF/HFpEF, regardless of baseline NYHA class.

ReachMD Healthcare Image
Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying PACE-CME…
but how about a more personalized experience?

Register for free